Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 15/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908654 | 0.87 | EPHX1 (0.50) | EPHX1KDM4EALDH1A1EPHX2KMT2A | |
| SCHEMBL15263332 | 0.87 | EPHX1 (0.57) | EPHX1KDM4EALDH1A1EPHX2KMT2A | |
| SCHEMBL965926 | 0.87 | — | — | |
| SCHEMBL1919598 | 0.81 | EPHX1 (0.65) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL1908656 | 0.80 | KDM4E (0.50) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL12436769 | 0.80 | EPHX1 (0.47) | EPHX1KDM4EALDH1A1EPHX2KMT2A | |
| SCHEMBL22722007 | 0.80 | EPHX1 (0.47) | EPHX1KDM4EALDH1A1EPHX2KMT2A | |
| SCHEMBL20233001 | 0.79 | EPHX1 (0.60) | EPHX1KDM4EALDH1A1EPHX2KMT2A | |
| SCHEMBL12801142 | 0.79 | EPHX2 (0.65) | EPHX1KDM4EALDH1A1EPHX2KMT2A | |
| SCHEMBL968340 | 0.79 | EPHX1 (0.63) | EPHX1KDM4EALDH1A1EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | EPHX1 2784/4885KDM4E 3758/4885ALDH1A1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.